Treatment-naïve HIV-1-infected adolescents initiating INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF)

GS-US-292-0106 and GS-US-236-0112
Week 24 Cross-Study Comparison

Hilda Kizito[1], *Aditya Gaur*[2], *Wasana Prasitsuebsai*[3], *Natella Rakhmanina*[4], *Kulkanya Chokephaibulkit*[5], *Jan Fourie*[6], *Linda-Gail Bekker*[7], *Yongwu Shao*[8], *Sean Bennett*[8], *Erin Quirk*[8]

[1]Joint Clinical Research Center, Kampala, Uganda; [2]St. Jude's Children's Research Hospital, USA; [3]HIV- Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; [4]George Washington University School of Medicine, Washington DC, USA; [5]Siriraj Hospital, Mahidol University, Bangkok, Thailand; [6]North West University South Africa; [7]Desmond Tutu HIV Centre, University of Cape Town, South Africa; [8]Gilead Sciences, Foster City, CA, USA

Abstract O19

7th International Workshop on HIV Pediatrics, Vancouver 2015

Tenofovir Alafenamide (TAF, GS-7340)
Novel Prodrug of Tenofovir



- 90% lower TFV levels minimizes renal and bone effects while maintaining high potency for suppressing HIV

1. Lee W et. Antimicr Agents Chemo 2005;49:1898-906; 2. Birkus G et al. Antimicr Agents Chemo 2007;51:543-50; 3. Babusis D, et al. Mol Pharm 2013;10:459-66; 4. Ruane P, et al. J Acquir Immune Defic Syndr 2013;63:449-55; 5. Sax P, et al. JAIDS 2014;2014;67:52-8. 6. Sax P, et al. Lancet 2015;385:2606-15.

Background: E/C/F/TAF and Stribild

- E/C/F/TAF and Stribild both contain elvitegravir (EVG) 150 mg, cobicistat (COBI) 150 mg, and emtricitabine (FTC) 200 mg
  - E/C/F/TAF contains TAF 10 mg
  - Stribild (E/C/F/TDF) contains TDF 300 mg
- In two phase 3 adult studies[1] E/C/F/TAF demonstrated
  - Noninferior efficacy to Stribild
  - Improvements in renal and bone safety
- Two single-arm open-label studies[2,3] of E/C/F/TAF and E/C/F/TDF conducted in treatment-naïve adolescents have shown
  - These STRs are well tolerated
  - Plasma levels of all components are similar to those in adults

1. Sax P, et al. Lancet 2015;385:2606-15; 2. Gaur A, et al. CROI 2014. Abstract 909; 3. Kizito H, et al. CROI 2015. Abstract 953.

Methods

- Cross-study comparison of 2 ongoing open-label, single-arm studies in treatment-naïve adolescents
  - Study 292-0106: E/C/F/TAF administered for 48 weeks (N=50)
  - Study 236-0112: E/C/F/TDF administered for 48 weeks (N=50)
- Primary endpoint: safety
- Secondary endpoint: viral suppression
- For both studies key inclusion/exclusion criteria:
  - Age ≥12 to < 18 years
  - Weight >35 kg
  - HIV-1 RNA >1000 copies/mL
  - No prior ARV therapy
  - CD4 count >100 cells/mm^3

Study Assessments and Analysis Methods

- Safety assessments
  - Adverse events and laboratory assessments: hematology, chemistry, renal tubular protein biomarkers
  - DXA of spine and total body less head (TBLH) at baseline and every 24 weeks
- Efficacy assessments
  - HIV-1 RNA (TaqMan 2.0) and CD4 count at every visit
  - Resistance testing in cases of confirmed virologic failure (HIV-1 RNA >400 copies/mL)
- Statistical methods
  - Cross-calibration between DXA scanner types (Hologic and Lunar)
  - Calculation of standard and height-adjusted Z-scores and predicted BMD change
  - Snapshot algorithm for HIV-1 RNA < 50 copies/mL at Week 24

Demographics and Baseline Characteristics

		E/C/F/TAF n=50	E/C/F/TDF n=50	p-value
Age	Years, median (range)	15 (12-17)	16 (12-17)	0.040
Sex	Male, n (%)	22 (44)	35 (70)	0.009
Country of Origin	Uganda, n (%)	30 (60)	0	
	South Africa	3 (6)	22 (44)	
	Thailand	6 (12)	14 (28)	
	United States	11 (22)	14 (28)	
eGFR (Schwartz)	mL/min/1.73 m^2, median	156.0	139.5	0.082
Spine BMD	g/cm^2, median	0.78	0.93	0.027
	Standard Z-score	-1.30	-0.72	0.20
	Height-adjusted Z-score	-0.54	+0.09	0.015

Baseline Disease Characteristics

		E/C/F/TAF n=50	E/C/F/TDF n=50	p value
HIV-1 RNA	Log_{10} copies/mL, mean (SD)	4.62 (0.59)	4.60 (0.55)	0.98
	>100,000 copies/mL, n (%)	11 (22)	10 (20)	0.81
CD4 Count	Cells/µL, median (Q1, Q3)	456 (332, 574)	402 (298, 486)	0.060
	<200 cells/µL, n (%)	4 (8)	2 (4)	
Mode of Infection	Vertical transmission, n (%)	32 (64)	17 (34)	
	Heterosexual sex	12 (24)	12 (24)	
	Homosexual sex	8 (16)	19 (38)	

Patient Disposition



Efficacy: Overview



- All subjects achieved HIV-1 RNA < 50 copies/mL by Week 12
- Proportion with HIV-1 RNA < 50 copies/mL at Week 24:
  - E/C/F/TAF 90% (45/50) and E/C/F/TDF 88% (44/50)
- Most failures were associated with decreased adherence
- No emergent resistance

Safety Overview

- No deaths or adverse events (AEs) leading to treatment discontinuation
- Most AEs mild or moderate and unrelated to study treatment
- No cases of proximal renal tubulopathy or Fanconi syndrome
- Serious adverse events:

E/C/F/TAF: 5 SAEs in 4 patients	E/C/F/TDF: 5 SAEs in 4 subjects
Urinary retention, neuropathic pain, constipation	1) Suicide gesture 2) Shigella dysentery, acute renal injury
Conduct disorder, polysubstance abuse, bipolar disorder	Pre-term labor
Intermediate uveitis, visual disorder*	Immune reconstitution inflammatory syndrome
1) Substance abuse 2) Suicidal ideation, suicide attempt	Acute asthma exacerbation

*Only treatment-related SAE and resolved without E/C/F/TAF interruption.

Most Common AEs

Patients, n (%)	E/C/F/TAF n=50	E/C/F/TDF n=50
Nausea	12 (24)	7 (14)
Upper respiratory tract infection	12 (24)	12 (24)
Respiratory tract infection	12 (24)	0
Diarrhea	11 (22)	7 (14)
Headache	9 (18)	12 (24)
Abdominal pain	8 (16)	2 (4)
Vomiting	7 (14)	9 (18)
Body tinea	6 (12)	0
Bronchopneumonia	6 (12)	0
Seborrheic dermatitis	6 (12)	0
Vitamin D deficiency	5 (10)	5 (10)
Dizziness	5 (10)	4 (8)
Cough	5 (10)	1 (2)
Acne	4 (8)	6 (12)
Pharyngitis	2 (4)	5 (10)

All AEs occuring in ≥10% of patients (either group) ordered by frequency in E/C/F/TAF group.

Creatinine and Cystatin C by Visit



- Median change in Cr (mg/dL) at Week 24: E/C/F/TAF **+0.08**, E/C/F/TDF **+0.08**
- Median change in eGFR (mL/min/1.73 m^2) at Week 24: E/C/F/TAF **-15.0**, E/C/F/TDF **-14.0**
- Slight decrease in Cystatin C (not affected by COBI) in both groups

Changes in Renal Tubular Biomarkers Through Week 24



Expressed as ratio of urine marker to urine creatinine. *p<0.05 in favor of E/C/F/TAF.

Changes in Spine Bone Mineral Density



		Predicted
Median (Q1, Q3) % Change	Week 24 (n=47)	+2.55 (+1.11, +4.54)
	Week 48 (n=23)	+5.09 (+2.23, +9.23)

Changes in Spine Bone Mineral Density



		Predicted	Actual
Median (Q1, Q3) % Change	Week 24 (n=47)	+2.55 (+1.11, +4.54)	+1.25 (-0.96, +4.11)
	Week 48 (n=23)	+5.09 (+2.23, +9.23)	+3.25 (+2.07, +6.47)

Changes in Spine Bone Mineral Density



		Predicted	Actual	Predicted
Median (Q1, Q3) % Change	Week 24 (n=47)	+2.55 (+1.11, +4.54)	+1.25 (-0.96, +4.11)	+1.55 (+1.11, +3.07)
	Week 48 (n=23)	+5.09 (+2.23, +9.23)	+3.25 (+2.07, +6.47)	+2.95 (+2.20, +6.08)

Changes in Spine Bone Mineral Density



		Predicted	Actual	Predicted	Actual	p-value
Median (Q1, Q3) % Change	Week 24 (n=47)	+2.55 (+1.11, +4.54)	+1.25 (-0.96, +4.11)	+1.55 (+1.11, +3.07)	-0.985 (-3.57, +0.95)	**0.009**
	Week 48 (n=23)	+5.09 (+2.23, +9.23)	+3.25 (+2.07, +6.47)	+2.95 (+2.20, +6.08)	+0.299 (-2.45, +3.04)	0.12

Conclusions

- Cross-study comparison limited by baseline differences (age, gender, geography, mode of transmission)
- Both groups exhibited rapid virologic response and high rates of virologic success at Week 24, with no emergent resistance
- E/C/F/TAF and E/C/F/TDF generally well tolerated
  - Mild-to-moderate gastrointestinal AEs
  - No AEs leading to treatment discontinuation
- Small observed increases in serum Cr, consistent with known effect of COBI in adults
- E/C/F/TAF decreased renal biomarkers of inflammation, similar to that observed in adult E/C/F/TAF phase 3 studies
- E/C/F/TAF group had increased median spine BMD at Week 24 (+1.3%) compared with a mean decrease (-0.9%) in E/C/F/TDF group
- These data support use of both regimens in treatment-naïve adolescents and continued evaluation of the potential renal and bone safety advantages of TAF

Acknowledgments

Principal Investigators:

H Kizito, A Gaur, W Prasitsuebsai, N Rakhmanina, M Rassool, R Chakraborty, C Orrell, P Kosalaraksa, W Luesomboon, J Batra , J Fourie, A Violari, R Kaplan, R Strehlau, G Cotton, G Latiff, K Chokephaibulkit, T Bunupuradah, J Ananworanich, J Burack, W Borkowsky, J Chen, D Futterman, C Rodriguez, J Schneider

The Gilead team:

D Podesta, M Hottman, S Goudar, M Myers, Y-P Liu, Y Shao, K Hasegawa, S Fong-Cohen, E Doyle, D Porter, A Coluci, S Bennett, M Fordyce, E Quirk, A Cheng

Our patients and their families

Studies of TAF-containing regimens to be presented at IAS 2015

- E/C/F/TAF and E/C/F/TDF in HIV-infected naïve adolescents (reprisal)
  - Gaur et al, oral abstract MOAB0104, Monday, 20-July, VCC
- Week 48 safety and efficacy of ~1400 HIV-infected adults suppressed on a TDF-containing regimen randomized to remain on TDF or switch to E/C/F/TAF
  - Mills et al, oral abstract TUAB0102, Tues 11:15-11:30, Ballroom C-D
- Week 48 renal and bone safety of E/C/F/TAF in HIV-infected adults with renal impairment
  - Gupta et al, oral abstract TUAB0103, Tues 11:30-11:45, Ballroom C-D
- Week 48 safety and efficacy of E/C/F/TAF in adults with HIV/HBV coinfection
  - Gallant et al, late breaker poster WELBPE13, Wed 12:30-14:30, Hall B
- Pharmacokinetics and drug interaction potential of TAF and rilpivirine
  - Begley et al, poster TUPEB279, Tues 12:30-14:30, Hall B
- Bioequivalence of two dosage strength fixed-dose combinations of F/TAF
  - Zack, et al, poster TUPEB275, Tues 12:30-14:30, Hall B